A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Henatinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and
antiangiogenic activities. This study is designed to evaluate the safety and tolerability of
Henatinib in patients with Advanced Solid Malignancies